HALOZYME THERAPEUTICS ($HALO) is expected to release its quarterly earnings data on Monday, November 3rd after market close, per Finnhub. Analysts are expecting revenue of $346,720,062 and earnings of $1.66 per share.
You can see Quiver Quantitative's $HALO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HALOZYME THERAPEUTICS Insider Trading Activity
HALOZYME THERAPEUTICS insiders have traded $HALO stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 35 sales selling 300,000 shares for an estimated $19,146,557.
- NICOLE LABROSSE (SVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 22,227 shares for an estimated $1,687,851.
- BERNADETTE CONNAUGHTON has made 0 purchases and 5 sales selling 6,000 shares for an estimated $445,217.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HALOZYME THERAPEUTICS Hedge Fund Activity
We have seen 279 institutional investors add shares of HALOZYME THERAPEUTICS stock to their portfolio, and 299 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,892,079 shares (-22.8%) from their portfolio in Q2 2025, for an estimated $202,465,949
- JPMORGAN CHASE & CO removed 1,439,307 shares (-58.2%) from their portfolio in Q2 2025, for an estimated $74,872,750
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,425,674 shares (+127.8%) to their portfolio in Q2 2025, for an estimated $74,163,561
- UBS GROUP AG added 1,173,156 shares (+334.0%) to their portfolio in Q2 2025, for an estimated $61,027,575
- QUBE RESEARCH & TECHNOLOGIES LTD added 986,069 shares (+inf%) to their portfolio in Q2 2025, for an estimated $51,295,309
- NUVEEN, LLC removed 948,397 shares (-66.4%) from their portfolio in Q2 2025, for an estimated $49,335,611
- JANE STREET GROUP, LLC added 926,602 shares (+2295.0%) to their portfolio in Q2 2025, for an estimated $48,201,836
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HALOZYME THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $HALO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Benchmark issued a "Buy" rating on 09/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/22/2025
- JMP Securities issued a "Market Outperform" rating on 08/06/2025
To track analyst ratings and price targets for HALOZYME THERAPEUTICS, check out Quiver Quantitative's $HALO forecast page.
HALOZYME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $HALO recently. We have seen 9 analysts offer price targets for $HALO in the last 6 months, with a median target of $75.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $65.0 on 10/27/2025
- Vikram Purohit from Morgan Stanley set a target price of $79.0 on 10/20/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $90.0 on 10/15/2025
- David Risinger from Leerink Partners set a target price of $70.0 on 10/14/2025
- Robert Wasserman from Benchmark set a target price of $90.0 on 09/24/2025
- Jason N. Butler from JMP Securities set a target price of $78.0 on 08/06/2025
- Mohit Bansal from Wells Fargo set a target price of $65.0 on 05/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
